Skip to main content

Option Care Health Value Stock - Dividend - Research Selection

Bioscrip

ISIN: US68404L2016 , WKN: A2PZEY

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient\'s homes, outpatient clinics, nursing facilities, physician\'s offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


BTSG and the Shift to Home Care as Margins Expand in 2026

2026-03-25
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.

Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?

2026-03-25
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.

BTSG Growth Drivers in 2026 Across Specialty and Providers

2026-03-25
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.

How The Option Care Health (OPCH) Story Is Shifting As Stelara Headwinds Fade And Targets Rise

2026-03-19
Analysts covering Option Care Health have been nudging price targets into the high US$30 range, while one outlier move of about US$10 highlights how views are being fine tuned rather than reset. These shifts line up with recent commentary around how long Stelara related profit headwinds might last and how much they really matter to the story now that this profit stream is under 1% of gross profit. As you read on, you will see how to track these target moves and what they may signal for the...

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare

2026-03-18
DGX, DVA, OPCH and ADUS gain attention as telehealth, AI adoption and aging population drive growth in home healthcare services.

4 Outpatient Home Health Stocks Gaining Attention Amid Market Shifts

2026-03-17
An aging population and rising AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, OPCH and ADUS stand to benefit.

3 Russell 2000 Stocks We Steer Clear Of

2026-03-12
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Option Care Health, CooperCompanies, Neogen, GoodRx, and Fortrea Shares Are Falling, What You Need To Know

2026-03-06
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

1 Stock Under $50 for Long-Term Investors and 2 We Turn Down

2026-03-06
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

A Look At Option Care Health’s Valuation As 2025 Results And 2026 Guidance Signal Resilient Growth

2026-02-28
Option Care Health (OPCH) is back in the spotlight after releasing fourth quarter and full year 2025 results. The company reported higher sales, steady profitability, active share repurchases, and updated 2026 guidance despite ongoing reimbursement and biosimilar pressures. See our latest analysis for Option Care Health. The latest earnings release has come alongside some share price volatility, with a 1 day share price return of 1.79% after the results, a 7 day share price return of 9.05%...